Litigation Details for ABBVIE INC. v. MSN PHARMACEUTICALS INC. (D.N.J. 2024)

ABBVIE INC. v. MSN PHARMACEUTICALS INC. (D.N.J. 2024)

Docket		Date Filed	2024-04-08
Court	District Court, D. New Jersey	Date Terminated	2025-12-03
Cause	15:1126 Patent Infringement	Assigned To	Jennifer Choe-Groves
Jury Demand	None	Referred To	Brendan Day
Patents	10,117,836; 11,717,515; 11,857,542; 11,925,709; 12,070,450; 12,168,004; 12,194,030; 12,220,408; 12,310,953; 12,458,632; 12,458,633; 8,754,096; 8,912,210; 9,499,545; 9,833,448
Attorneys	MARK M. MAKHAIL
Firms	McCarter and English, LLP
Link to Docket	External link to docket

Details for ABBVIE INC. v. MSN PHARMACEUTICALS INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-04-08				External link to document
2024-04-08	1	Complaint	.S. Patent No. 10,117,836, # 2 Exhibit B - U.S. Patent No. 11,717,515, # 3 Exhibit C - U.S. Patent No.…No. 11,857,542, # 4 Exhibit D - U.S. Patent No. 11,925,709, # 5 Civil Cover Sheet)(LINARES, JOSE) (Entered… 8 April 2024 3:24-cv-04662 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: AbbVie Inc. v. MSN Pharmaceuticals Inc. (3:24-cv-04662)

Last updated: July 14, 2026

Executive summary: AbbVie Inc. sued MSN Pharmaceuticals Inc. under the Hatch-Waxman patent litigation framework in the U.S. District Court for the District of New Jersey in case 3:24-cv-04662. The filing is an active federal patent dispute tied to FDA small-molecule generic entry. The docket currently supports a proceeding posture consistent with a Paragraph IV-type challenge to one or more Orange Book-listed AbbVie patents. Specific patent numbers, asserted claims, and settlement or dismissal status cannot be reliably stated from the information provided.

What is the litigation posture for AbbVie Inc. v. MSN Pharmaceuticals Inc. 3:24-cv-04662?

Direct answer: This is a U.S. federal patent infringement case filed by AbbVie against MSN Pharmaceuticals in case 3:24-cv-04662, in the District of New Jersey, at the start of the 2024 filing cycle. The litigation posture aligns with Hatch-Waxman enforcement actions against an FDA-initiated generic application.

Where is the case filed and what court controls it?

• Court: U.S. District Court (District of New Jersey)
• Case number: 3:24-cv-04662
• Parties: AbbVie Inc. (plaintiff) and MSN Pharmaceuticals Inc. (defendant)

What stage is the case in?

Direct answer: The dispute is active enough to exist as a federal docketed action, but the provided inputs do not include the complaint, scheduling order, Markman date, claim construction posture, or dispositive motion dates. Those items control practical infringement risk and near-term timeline.

What patents are being asserted in AbbVie v. MSN Pharmaceuticals?

Direct answer: The asserted patents and specific asserted claims are not identifiable from the provided material. Patent numbers and claim sets are required to analyze strength, likely construction issues, and design-around pathways.

How to assess strength once asserted patents are known

Once asserted patents are identified, the strength map usually breaks down into:

• Core composition vs. formulation vs. method-of-use: determines whether a generic can “design around” by changing formulation or claims without changing active ingredient
• Validity risk profile: novelty, obviousness, enablement, indefiniteness
• Enforceability defenses: prosecution history estoppel and claim scope limitations
• Infringement theory: literal vs. doctrine of equivalents, ANDA product mapping, equivalence barriers

Is this case tied to Paragraph IV certification and an ANDA?

Direct answer: The case name and structure match common Hatch-Waxman patent litigation patterns, but the provided inputs do not include the ANDA number or Paragraph IV certification details. Without those, a definitive Paragraph IV label for this docket cannot be stated.

What filing artifacts usually confirm Paragraph IV

• Complaint allegations referencing the FDA approval pathway and certification
• Reference to the Orange Book “patent list” for the drug at issue
• Recitals on timing, 30-month stay, or amendments to certifications

Why the ANDA details matter for litigation economics

• The drug name determines the relevant patent family and the technical claim construction themes
• The formulation strength controls whether the infringement chart turns on specific excipients, coating systems, release profile, or dosing unit features
• The manufacturing site and process can matter if the asserted claims include manufacturing method elements

When does AbbVie’s exclusivity and patent protection run out, and how does it shape the case?

Direct answer: The exclusivity/patent expiration timeline cannot be computed from the case information alone because the drug and asserted patent numbers are not specified.

What drives the exclusivity clock in Hatch-Waxman

For U.S. FDA small-molecule drugs:

• Orange Book listed patents define the infringement window
• 30-month stay can delay FDA approval after a Paragraph IV notice
• A generic’s launch timing depends on court outcomes (infringement vs. invalidity findings) and any settlement “entry-forcing” terms

What generic entry risks exist for MSN Pharmaceuticals if AbbVie wins?

Direct answer: Without the asserted patent scope and claim elements, the specific entry risk level cannot be quantified. In general, a win for AbbVie typically prevents FDA approval or triggers an FDA approval redesign that avoids the specific claim coverage.

Common risk outcomes

• Injunction against launch: the generic remains off-market
• Carve-outs if only some claims are enjoined: potential partial workarounds
• Redesign triggers: label, formulation, dissolution profile, or manufacturing process changes

What settlement outcomes are typical in cases like this?

Direct answer: Settlement terms are not included in the provided inputs, so the presence or absence of a settlement cannot be stated.

Typical settlement structures that affect business planning

• “At-risk” launch offsets with delayed entry
• License agreements granting rights under specific patents
• Staggered launch by strength, package type, or dosage form
• Design-around covenants defining permitted product differences
• Stipulated dismissal following payment or royalty structure

What patent litigation defenses does MSN likely raise in AbbVie cases?

Direct answer: The available inputs do not specify MSN’s affirmative defenses. Standard defenses in this case category typically include non-infringement, invalidity, and procedural or jurisdictional defenses tied to FDA notice sufficiency.

Key technical defenses to evaluate once claims are known

• Non-infringement mapping gaps: missing structural elements, dosage form parameters, or method steps
• Prior art obviousness: obvious combinations aimed at composition/formulation elements
• Indefiniteness: claim language that fails to inform with reasonable certainty
• Non-enabled claims: speculative or overbroad ranges

How does claim construction usually affect AbbVie vs. generic litigation outcomes?

Direct answer: Claim construction often determines whether the generic can argue non-infringement by adopting different parameter ranges or process steps. The specific claim terms at issue cannot be evaluated from the provided inputs.

Claim construction topics that often decide infringement

• Release/dissolution parameters
• Particle size, polymorph control, or crystallinity definitions
• Coating composition and thickness
• Stabilizer selection and concentration ranges
• Method steps with order-of-operations limitations

What is the Orange Book status of the drug in dispute?

Direct answer: The drug name and Orange Book listing are not provided. Orange Book status includes:

• Patent numbers listed for the NDA/ANDA reference product
• Expiration dates and listed exclusivity blocks (if any)
• Whether the patents are drug substance, drug product, or method-of-use

How strong is AbbVie’s patent estate in litigation like 3:24-cv-04662?

Direct answer: Strength cannot be calculated without the asserted patent family and key expiration dates. A robust estate analysis requires:

• the number of asserted patents
• the overlap among families
• whether they target composition, formulation, and method-of-use concurrently
• whether any asserted patents are expected to be early-expiring or subject to high invalidity risk

What is the competitive landscape and which other companies often co-litigate?

Direct answer: No co-defendant or co-litigant details are provided.

What to look for once the drug is identified

• Other generic applicants challenging the same Orange Book patents
• Prior Paragraph IV litigations by competitors in the same patent family
• Whether the asserted patents already survived similar invalidity challenges

What commercial exposure does the case create for AbbVie and MSN?

Direct answer: Commercial exposure depends entirely on the drug’s revenue, the number of remaining patents, and expected launch timing. Those drivers are not given.

How to size exposure once the drug is known

• AbbVie net sales for the reference product and loss of market share
• Generic drug adoption rates post-launch
• Likelihood of settlement vs. judgment
• Whether the product is supplied in multiple strengths that affect “partial launch” scenarios

Procedural milestones that determine near-term outcomes

Direct answer: The docket milestones are not included in the provided inputs. For business planning, the controlling milestones are:

• complaint service and answer deadlines
• initial infringement contentions and invalidity contentions
• claim construction hearing (Markman) and ruling schedule
• expert discovery, dispositive motions, and trial date
• post-trial injunction and FDA-specific enforcement steps

Key Takeaways

• Case identification: AbbVie Inc. v. MSN Pharmaceuticals Inc., federal patent litigation 3:24-cv-04662 in the District of New Jersey.
• What can be concluded from provided info: the matter is a docketed infringement dispute consistent with Hatch-Waxman-type generic challenges.
• What cannot be concluded from provided info: asserted patent numbers, claims, drug identity, Orange Book status, exclusivity timelines, and litigation outcome status.
• Business implication: the investment and licensing read-through for this docket depends on the specific patent family asserted and the court’s claim construction trajectory, which must be tied to the Orange Book listing for the relevant NDA/ANDA.

FAQs

1) What is the fastest way to determine whether AbbVie v. MSN is a Paragraph IV case?
Review the complaint’s allegations for FDA pathway language, certification references, and Orange Book timing statements tied to an ANDA notice.

2) Which documents control whether a generic can launch during litigation?
The court’s scheduling order, injunction rulings (if any), and any settlement dismissal terms that define FDA approval conditions.

3) Do method-of-use or formulation patents change the generic design-around options?
Yes. Method-of-use claims can constrain labeling and prescribed use, while formulation patents can sometimes be avoided through dissolution, excipient selection, or parameter changes.

4) How does claim construction timing impact settlement leverage?
Markman rulings narrow infringement/invalidity paths and typically shift parties toward settlement when claim scope becomes clear.

5) What metrics best estimate commercial risk from a pending AbbVie patent case?
Drug revenue at risk, number of unexpired asserted patents, expected trial/decision timeline, and the feasibility of product redesign or labeling changes.

References

No source documents were provided in the prompt to cite.